JP2023036708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023036708A5 JP2023036708A5 JP2022199092A JP2022199092A JP2023036708A5 JP 2023036708 A5 JP2023036708 A5 JP 2023036708A5 JP 2022199092 A JP2022199092 A JP 2022199092A JP 2022199092 A JP2022199092 A JP 2022199092A JP 2023036708 A5 JP2023036708 A5 JP 2023036708A5
- Authority
- JP
- Japan
- Prior art keywords
- citrate
- crystals
- crystal
- degrees
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 17
- 238000000634 powder X-ray diffraction Methods 0.000 claims 9
- 230000001747 exhibiting effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000001860 citric acid derivatives Chemical class 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000001757 thermogravimetry curve Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024174009A JP2025020120A (ja) | 2018-08-31 | 2024-10-03 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725805P | 2018-08-31 | 2018-08-31 | |
| US62/725,805 | 2018-08-31 | ||
| US16/517,369 | 2019-07-19 | ||
| US16/517,369 US10562930B1 (en) | 2018-08-31 | 2019-07-19 | Salts and crystal forms of GABAA positive allosteric modulator |
| PCT/US2019/049103 WO2020047434A1 (en) | 2018-08-31 | 2019-08-30 | Salts and crystal forms of gabaa positive allosteric modulator |
| JP2020517339A JP7199739B2 (ja) | 2018-08-31 | 2019-08-30 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517339A Division JP7199739B2 (ja) | 2018-08-31 | 2019-08-30 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024174009A Division JP2025020120A (ja) | 2018-08-31 | 2024-10-03 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023036708A JP2023036708A (ja) | 2023-03-14 |
| JP2023036708A5 true JP2023036708A5 (enExample) | 2023-06-15 |
Family
ID=69528249
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517339A Active JP7199739B2 (ja) | 2018-08-31 | 2019-08-30 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
| JP2022199092A Pending JP2023036708A (ja) | 2018-08-31 | 2022-12-14 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
| JP2024174009A Pending JP2025020120A (ja) | 2018-08-31 | 2024-10-03 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517339A Active JP7199739B2 (ja) | 2018-08-31 | 2019-08-30 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024174009A Pending JP2025020120A (ja) | 2018-08-31 | 2024-10-03 | Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10562930B1 (enExample) |
| EP (2) | EP3710465B1 (enExample) |
| JP (3) | JP7199739B2 (enExample) |
| KR (1) | KR102845326B1 (enExample) |
| CN (1) | CN113473991A (enExample) |
| AU (1) | AU2019333310B8 (enExample) |
| BR (1) | BR112021003727A2 (enExample) |
| CA (1) | CA3111193A1 (enExample) |
| IL (1) | IL281143B2 (enExample) |
| MA (1) | MA50921A (enExample) |
| MX (1) | MX2021002382A (enExample) |
| TW (2) | TWI850138B (enExample) |
| WO (1) | WO2020047434A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016061527A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019397565A1 (en) * | 2018-12-14 | 2021-07-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| WO2022006541A1 (en) * | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| JP2024506942A (ja) * | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| WO2022231309A1 (ko) | 2021-04-27 | 2022-11-03 | 경북대학교 산학협력단 | 저분자 콜라겐을 유효성분으로 포함하는 근감소증의 예방 또는 개선용 식품 조성물 및 약학적 조성물 |
| WO2023159035A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| WO2023164386A1 (en) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| YU77701A (sh) | 1999-04-29 | 2005-07-19 | Euro-Celtique S.A. | 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM |
| CN1688288A (zh) * | 2002-08-05 | 2005-10-26 | 巴克斯特国际公司 | 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑 |
| WO2004072079A1 (en) | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
| WO2005007600A2 (en) | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
| EP1656353B1 (en) | 2003-08-14 | 2010-01-27 | F. Hoffmann-La Roche Ag | Gabanergic modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| EP1888080B1 (en) | 2005-06-09 | 2010-04-14 | Euro-Celtique S.A. | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| CN103936716B (zh) * | 2009-04-23 | 2016-09-07 | 施万呼吸有限责任公司 | 具蕈毒碱受体拮抗剂和β2肾上腺素受体激动剂活性的二酰胺化合物 |
| MX2012009821A (es) * | 2010-02-24 | 2012-10-09 | Univ Ramot | Formas cristalinas de la sal de tri-mesilato de perfenazina-gaba y proceso para producirlas. |
| SG190224A1 (en) * | 2010-11-11 | 2013-06-28 | Akron Molecules Gmbh | Compounds and methods for treating pain |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| PL3024458T3 (pl) | 2013-07-24 | 2018-08-31 | Commissariat à l'énergie atomique et aux énergies alternatives | Zastosowanie flekainidu jako środka anty-koneksynowego oraz sposób wzmacniania efektów działania leku psychotropowego |
| AU2015296117B2 (en) * | 2014-08-01 | 2019-05-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016061527A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| US10420773B2 (en) | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019397565A1 (en) * | 2018-12-14 | 2021-07-08 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| CN113226326B (zh) | 2018-12-17 | 2024-09-20 | 细胞内治疗公司 | 有机化合物 |
| EP3934655A4 (en) | 2019-03-04 | 2022-12-21 | Praxis Precision Medicines, Inc. | PERIMENOPAUSE AND MENOPAUSE TREATMENT METHODS |
| WO2020185710A1 (en) | 2019-03-08 | 2020-09-17 | Alairion, Inc. | Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor |
| WO2021025985A1 (en) | 2019-08-02 | 2021-02-11 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
| AU2020358002A1 (en) | 2019-10-02 | 2022-04-21 | Praxis Precision Medicines, Inc. | Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists |
| WO2021168106A1 (en) | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| WO2022006541A1 (en) | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
| WO2022040545A1 (en) | 2020-08-20 | 2022-02-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2024506942A (ja) | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| CN117715641A (zh) | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| WO2023159094A2 (en) | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
| WO2023211856A1 (en) | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Methods for the treatment of neurological disorders |
-
2019
- 2019-07-19 US US16/517,369 patent/US10562930B1/en active Active
- 2019-08-30 MX MX2021002382A patent/MX2021002382A/es unknown
- 2019-08-30 EP EP19842855.9A patent/EP3710465B1/en active Active
- 2019-08-30 EP EP24194131.9A patent/EP4458357A3/en active Pending
- 2019-08-30 IL IL281143A patent/IL281143B2/en unknown
- 2019-08-30 TW TW112141287A patent/TWI850138B/zh active
- 2019-08-30 AU AU2019333310A patent/AU2019333310B8/en active Active
- 2019-08-30 JP JP2020517339A patent/JP7199739B2/ja active Active
- 2019-08-30 TW TW108131297A patent/TWI823999B/zh active
- 2019-08-30 CA CA3111193A patent/CA3111193A1/en active Pending
- 2019-08-30 CN CN201980071246.9A patent/CN113473991A/zh active Pending
- 2019-08-30 BR BR112021003727-6A patent/BR112021003727A2/pt unknown
- 2019-08-30 KR KR1020217009437A patent/KR102845326B1/ko active Active
- 2019-08-30 MA MA050921A patent/MA50921A/fr unknown
- 2019-08-30 WO PCT/US2019/049103 patent/WO2020047434A1/en not_active Ceased
- 2019-11-27 US US16/698,057 patent/US10927141B2/en active Active
-
2021
- 2021-01-07 US US17/143,602 patent/US20220024967A1/en not_active Abandoned
-
2022
- 2022-12-14 JP JP2022199092A patent/JP2023036708A/ja active Pending
-
2023
- 2023-12-05 US US18/529,117 patent/US12404297B2/en active Active
-
2024
- 2024-10-03 JP JP2024174009A patent/JP2025020120A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023036708A5 (enExample) | ||
| JP2024105460A5 (enExample) | ||
| JP2020128376A5 (enExample) | ||
| JP2021530565A5 (enExample) | ||
| JP2023082086A5 (enExample) | ||
| JP2023002516A5 (enExample) | ||
| JP2022068321A5 (enExample) | ||
| JP2012527442A5 (enExample) | ||
| JP2009521414A5 (enExample) | ||
| JP2010132669A (ja) | ストロンチウムラネレートのアルファー（α）−結晶形、その製造方法、及びそれを含む医薬組成物 | |
| JP2024177569A5 (enExample) | ||
| JP2019504103A5 (enExample) | ||
| Khandavilli et al. | High solubility crystalline hydrates of Na and K furosemide salts | |
| JP2023109937A5 (enExample) | ||
| JP2013538849A5 (enExample) | ||
| CN114430736A (zh) | 含有n杂五元环的衣壳蛋白装配抑制剂的晶型及其应用 | |
| JP7314319B2 (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| JPWO2020257573A5 (enExample) | ||
| JPWO2021033729A5 (enExample) | ||
| JP2016537326A5 (enExample) | ||
| JP2022088524A5 (enExample) | ||
| JP2016510767A5 (enExample) | ||
| CN113348166A (zh) | 喹啉衍生物的结晶 | |
| JPWO2020210669A5 (enExample) | ||
| JP6818031B2 (ja) | モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途 |